National Comprehensive Cancer Network guidelines recommend that patients newly diagnosed with mNSCLC testing positive for actionable molecular biomarker or genomic tumor driver mutation, such as epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), or proto-oncogene tyrosine-protein kinase ROS enzyme (ROS1), be treated with a tyrosine kinase inhibitor (TKI) specific to the particular mutation or molecular biomarker-directed therapy (15). The gene discussed is ALK; the disease is neoplasm.